Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide

Biochemistry
Brian M AustenOmar M A El-Agnaf

Abstract

Convergent biochemical and genetic evidence suggests that the formation of beta-amyloid (Abeta) deposits in the brain is an important and, probably, seminal step in the development of Alzheimer's disease (AD). Recent studies support the hypothesis that Abeta soluble oligomers are the pathogenic species that prompt the disease. Inhibiting Abeta self-oligomerization could, therefore, provide a novel approach to treating the underlying cause of AD. Here, we designed potential peptide-based aggregation inhibitors containing Abeta amino acid sequences (KLVFF) from part of the binding region responsible for Abeta self-association (residues 16-20), with RG-/-GR residues added at their N- and C-terminal ends to aid solubility. Two such peptides (RGKLVFFGR, named OR1, and RGKLVFFGR-NH2, named OR2) were effective inhibitors of Abeta fibril formation, but only one of these peptides (OR2) inhibited Abeta oligomer formation. Interestingly, this same OR2 peptide was the only effective inhibitor of Abeta toxicity toward human neuroblastoma SH-SY5Y cells. Our data support the idea that Abeta oligomers are responsible for the cytotoxic effects of Abeta and identify a potential peptide inhibitor for further development as a novel therapy for AD.

References

Apr 12, 1996·The Journal of Biological Chemistry·L O TjernbergC Nordstedt
Nov 22, 1996·The Journal of Biological Chemistry·J GhantaR M Murphy
Dec 21, 2004·Nature Neuroscience·James P ClearyKaren H Ashe
Jan 25, 2007·Nature Reviews. Molecular Cell Biology·Christian Haass, Dennis J Selkoe
Feb 9, 2007·Journal of Neurochemistry·Dominic M Walsh, Dennis J Selkoe

❮ Previous
Next ❯

Citations

Feb 23, 2013·ACS Chemical Neuroscience·Yuan LuoIlya Bezprozvanny
Dec 16, 2011·Proceedings of the National Academy of Sciences of the United States of America·Joseph M PerchiaccaPeter M Tessier
Mar 10, 2012·Science·Arthur LaganowskyDavid Eisenberg
Sep 25, 2012·Chemical Communications : Chem Comm·Jing-Wen MaYan-Mei Li
Nov 27, 2015·Journal of Neurochemistry·Metta K JanaGiuseppe D Ciccotosto
Jul 27, 2012·Bioorganic & Medicinal Chemistry·Yun Suk LeeKye Jung Shin
Jan 14, 2016·Amino Acids·Marta SosnowskaElżbieta Jankowska
Aug 19, 2014·ACS Chemical Neuroscience·Qiuming WangJie Zheng
Dec 15, 2010·Journal of Molecular Graphics & Modelling·Andrew Hung, Irene Yarovsky
Jul 28, 2010·Bioorganic & Medicinal Chemistry·Partha Pratim BosePer I Arvidsson
Jun 3, 2010·Biochemical and Biophysical Research Communications·Sourajit M MustafiCarl Frieden
Apr 3, 2014·ACS Chemical Neuroscience·J Phillip TurnerShannon L Servoss
Jul 1, 2014·Langmuir : the ACS Journal of Surfaces and Colloids·Anna AssarssonCelia Cabaleiro-Lago
Feb 18, 2009·Angewandte Chemie·Valeria CastellettoDarrin Pochan
Oct 30, 2010·Chembiochem : a European Journal of Chemical Biology·Yang HuJin Ryoun Kim
Jul 22, 2010·Journal of Peptide Science : an Official Publication of the European Peptide Society·Valeria CastellettoEduardo M Castaño
Sep 3, 2011·Chemistry : a European Journal·Michal RichmanShai Rahimipour
Jul 5, 2008·Biophysical Journal·M I SmithC J Roberts
Nov 6, 2015·ACS Applied Materials & Interfaces·Nibedita PradhanNikhil R Jana
Aug 21, 2015·Organic & Biomolecular Chemistry·Shah Md Abdur RaufBahareh Honarparvar
Oct 11, 2011·Colloids and Surfaces. B, Biointerfaces·Michael I SmithAthene M Donald
Jun 16, 2015·Molecular BioSystems·Edwin AorahaJin Ryoun Kim
Dec 17, 2014·Physical Chemistry Chemical Physics : PCCP·R Pouplana, J M Campanera
Feb 24, 2015·RSC Advances·K SivanesamN Andersen
Jun 28, 2016·ACS Chemical Neuroscience·Xiaomeng LuRegina M Murphy
Jul 14, 2016·Physical Chemistry Chemical Physics : PCCP·Baiping RenJie Zheng
Nov 5, 2016·Nanomedicine : Nanotechnology, Biology, and Medicine·Maria GregoriDavid Allsop
Feb 23, 2018·Frontiers in Aging Neuroscience·Mohammad H BaigInho Choi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.